Antibody Information

Antibody Information

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)

Citation

Visitor Map

Correspondence

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

RG7787 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 24 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.4 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.7 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast carcinoma	SUM149PT cells		CVCL_3422
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.5 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.5 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	.	L55S cells		Homo sapiens
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.7 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast ductal carcinoma	HCC70 cells		CVCL_1270
Experiment 13 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 14 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 15 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 16 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	.	L55S cells		Homo sapiens
Experiment 17 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Breast carcinoma	SUM149PT cells		CVCL_3422
Experiment 18 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	KLM-1 cells		CVCL_5146
Experiment 19 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 20 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Skin squamous cell carcinoma	A-431 cells		CVCL_0037
Experiment 21 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	35 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Peritoneal malignant mesothelioma	HAY cells		CVCL_N813
Experiment 22 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	40 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152
Experiment 23 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	40 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 24 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 ng/mL	Positive MSLN expression (MSLN+++/++)
Method Description	RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

References

Ref 1	Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Res. 2016 Mar 15;76(6):1560-8. doi: 10.1158/0008-5472.CAN-15-2401. Epub 2015 Dec 30.

Antibody ID

Antibody Name

Anti-MSLN antibody Fab fragment

Antibody Type

Monoclonal antibody (mAb)

Antibody Subtype

Humanized IgG1 Fab

Antigen Name

Mesothelin (MSLN)

Antigen Info

Click to Show/Hide the Sequence Information of This Antibody